A trial of SB 913 for the treatment of beta-thalassaemia
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2017
At a glance
- Drugs SB 913 (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- 06 Jan 2017 According to a Sangamo Therapeutics media release, this trial was originally conducted by Sangamo BioSciences but later on this company's name changed to Sangamo Therapeutics.
- 05 May 2016 New trial record
- 02 May 2016 According to a Sangamo BioSciences media release, the company plans to submit investigational new drug (IND) application for SB 913 for beta-thalassaemia in the first half of 2016.